France Begins Reimbursement for Wegovy and Mounjaro Under Strict Criteria

Starting this Monday, the French Assurance maladie has begun providing 65% reimbursement for Wegovy and Mounjaro, two anti-obesity medications, for patients diagnosed with severe or massive obesity. This new policy mandates strict clinical criteria and requires initial prescriptions to be issued exclusively by doctors in specialized obesity centers, such as a Centre spécialisé de l’obésité (CSO).

Strict Access Criteria and Medical Oversight

The rollout of this reimbursement program is highly regulated to ensure patient safety and program compliance. According to the Ministry of Health, while approximately one million people could theoretically meet the eligibility requirements, access remains restricted through a mandatory, secure prescription process. Patients must utilize a specific medical form, and their initial treatment plan must be authorized by a practitioner within a specialized obesity structure.

Did You Know? The French market for obesity treatments has seen rapid growth, with current valuations exceeding 150 million euros—a figure more than twenty times higher than the market level recorded in 2024.

Operational Challenges for Pharmacies

Pharmacists do not anticipate an immediate surge in pharmacy traffic due to these strict administrative hurdles. Éric Myon, a Parisian pharmacist and secretary general of the Union nationale des pharmacies de France (UNPF), stated to the AFP that the primary focus for pharmacies will be verifying the credentials of practitioners authorized to issue the initial prescriptions. Myon noted that because specialized centers face capacity constraints, they cannot immediately accommodate every patient, meaning many individuals will continue to finance their own treatments in the short term.

WeGovy, Ozempic or Mounjaro? How a new wave of weight loss drugs could transform the diet industry

Expert Insight: This policy shift represents a transition from elective usage to a state-regulated medical framework. By requiring both medication and mandated lifestyle changes—including diet and physical activity—the system aims to integrate pharmacological intervention into a broader clinical strategy, though the long-term effectiveness of monitoring these lifestyle conditions remains a subject of professional debate.

What Happens Next?

The financial impact of this inclusion is projected to reach approximately 100 million euros for the Assurance maladie by 2027. Moving forward, the market may evolve as private health insurance companies observe the public sector’s progress. These private providers could potentially offer broader reimbursement options for patients who do not qualify for the current public program. Additionally, the future introduction of oral versions of these medications may influence the speed and scale at which these treatments are adopted across the country.

Frequently Asked Questions

Who is eligible for the 65% reimbursement?
Reimbursement is reserved for patients suffering from severe or massive obesity who meet specific medical criteria and receive an initial prescription from a doctor in a specialized obesity center.

Why is the rollout expected to be slow?
According to Éric Myon of the UNPF, the process requires strict verification of authorized practitioners and specialized centers currently face limitations in their capacity to receive all potential patients in the coming weeks.

Are there other requirements for patients besides the medication?
Yes, the reimbursement is conditional upon the patient following an adapted diet and increasing their physical activity levels, though experts have expressed questions regarding how these conditions will be effectively monitored.

How do you view the balance between medical intervention and lifestyle requirements in treating obesity?